- Raised $16M Series A led by OurCrowd, Mar 2020
- Raised $500k convertible note led by OurCrowd, Jul 2022
- Raised $500k convertible note, Nov 2021
About
MigVax is a biotechnology company established in 2020, focused on developing innovative oral subunit vaccines for humans, starting with COVID-19. The company leverages advanced methodologies and a multidisciplinary research team to create vaccines that activate all arms of the immune system, offering comprehensive protection. It aims to address logistical challenges of current vaccines and provide safer, more accessible options, including oral and protein-based formulations. MigVax is an affiliate of The Migal Galilee Research Institute. The Migal Galilee Research Institute previously developed a vaccine against infectious bronchitis virus, a coronavirus strain affecting poultry, and MigVax is adapting this technology for human use. The company's vaccine platform aims to generate multi-variant vaccines and uses an AI-based prediction methodology for early warning of virus mutations.
Funding history · 4 rounds · $21.3M total
Headcount over time
Q&A
- What is MigVax's primary focus?
- MigVax is a biotechnology company established in 2020, focused on developing innovative oral subunit vaccines for humans, starting with COVID-19.
- How much funding has MigVax raised in total?
- MigVax has raised a total of $21,300,000 in funding.
- Which organization provided a grant to MigVax in September 2024?
- In September 2024, MigVax received a grant of $600,418 from the Bill & Melinda Gates Foundation.
- Who led MigVax's B Round funding in April 2020?
- OurCrowd led MigVax's B Round funding of $12,000,000 in April 2020.
- What was the amount of the grant MigVax received in November 2021 and from whom?
- In November 2021, MigVax received a grant of $4,300,000 from the Coalition for Epidemic Preparedness Innovations (CEPI).
- What is the current employee count for MigVax?
- MigVax currently has 9 employees, falling within the 1-10 employee bucket.
- When was MigVax founded?
- MigVax was founded in March 2020.
- What is MigVax's connection to the Migal Galilee Research Institute?
- MigVax is an affiliate of The Migal Galilee Research Institute, which previously developed a vaccine against infectious bronchitis virus, a coronavirus strain affecting poultry. MigVax is adapting this technology for human use.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | migvax.com/ |
|---|---|
| linkedin.com/company/82100394 |
Identifiers & details
| Legal name | MigVax Ltd. |
|---|---|
| Founded | 2020-3 |
| Employees (exact) | 9 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | migvax.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516178084 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-03-18 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | התרשיש 5 קריית שמונה |